531599 Stock Overview
Manufactures and markets pharmaceutical products in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
My Notes
Capture your thoughts, links and company narrative
FDC Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹491.25 |
| 52 Week High | ₹659.00 |
| 52 Week Low | ₹390.45 |
| Beta | 0.27 |
| 1 Month Change | 1.49% |
| 3 Month Change | -12.94% |
| 1 Year Change | 25.32% |
| 3 Year Change | 69.34% |
| 5 Year Change | 135.50% |
| Change since IPO | 11,391.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| 531599 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -2.3% | 0.8% | -4.2% |
| 1Y | 25.3% | 39.7% | 19.1% |
Return vs Industry: 531599 underperformed the Indian Pharmaceuticals industry which returned 39.7% over the past year.
Return vs Market: 531599 exceeded the Indian Market which returned 19.1% over the past year.
Price Volatility
| 531599 volatility | |
|---|---|
| 531599 Average Weekly Movement | 4.3% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: 531599 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 531599's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1936 | 6,659 | Nandan Chandavarkar | www.fdcindia.com |
FDC Limited manufactures and markets pharmaceutical products in India and internationally. The company offers specialized formulations for various therapeutic segments, including anti-infective, gastrointestinal, ophthalmic, vitamins, minerals, dietary supplements, cardiac, anti-diabetes, respiratory, gynaecology, dermatology, and analgesics; and anti-oxidants, balanced energy and protein drinks, and vitamins and nutraceuticals, as well as various active pharmaceutical ingredients. It provides its products under the Zifi, Zefu, Zocon, Amodep-AT, Zathrin, Mycoderm, Zoxan, Cotaryl, Pyrimon DF, Zipod, Vitcofol, Ziglim, Ziglim Plus 2, Electral, and Enerzal brand names.
FDC Limited Fundamentals Summary
| 531599 fundamental statistics | |
|---|---|
| Market cap | ₹79.98b |
| Earnings (TTM) | ₹3.17b |
| Revenue (TTM) | ₹20.72b |
25.3x
P/E Ratio3.9x
P/S RatioIs 531599 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 531599 income statement (TTM) | |
|---|---|
| Revenue | ₹20.72b |
| Cost of Revenue | ₹7.53b |
| Gross Profit | ₹13.20b |
| Other Expenses | ₹10.03b |
| Earnings | ₹3.17b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 19.45 |
| Gross Margin | 63.68% |
| Net Profit Margin | 15.28% |
| Debt/Equity Ratio | 0% |
How did 531599 perform over the long term?
See historical performance and comparisonDividends
2.0%
Current Dividend Yield26%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 03:24 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
FDC Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Centrum Broking Limited |
| Kameswari V. S. Chavali | FirstCall Research |